Amyloidosis cutis dyschromia
MONDO:0017906Amyloidosis cutis dyschromia is a rare primary cutaneous amyloidosis characterized by macular or reticulate hyperpigmentation with symmetrically distributed guttate hypo- and hyperpigmented lesions which progress gradually over the years to involve almost the entire body (with relative sparing of the face, hands, feet and neck). Patients are usually asymptomatic, however mild pruritus may be associated. Amyloid deposition in the papillary dermis is observed on skin biopsy. Systemic amyloidosis is not present and association with generalized morphea, atypical Parkinsonism, spasticity, motor weakness or colon carcinoma is rare.
Also known as: amyloidosis cutis dyschromica
3 clinical trials for this condition and its sub-types, 0 tagged with Amyloidosis cutis dyschromia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
App-Based diet tracking tested in rare disease
Knowledge-focused Recruiting nowThis pilot trial is testing whether amyloidosis patients can use the MyFitnessPal smartphone app to track their daily food and supplement intake for 8 weeks. The goal is to see if this low-cost method is feasible for studying malnutrition and weight loss in this condition. Forty …
Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New biobank aims to unlock secrets of rare amyloidosis
Knowledge-focused Recruiting nowThis study is creating a biobank and data registry for people with amyloidosis, a rare disease where abnormal proteins build up in organs. Researchers will collect blood, urine, tissue samples, and medical information from 505 participants over time. The goal is to store these ma…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Scientists launch massive amyloid sample collection
Knowledge-focused Recruiting nowThis study is creating a large collection of blood, urine, and tissue samples from up to 10,000 people with amyloid diseases (like multiple myeloma). The goal is to store these samples and health data for future research to better understand these conditions. Participants do not …
Sponsor: Boston Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC